India's Manipal College prepares for nanotech drug-delivery revolution

The Times of India has a feature on India's Manipal College of Pharmaceutical Sciences (MCOPS) and its role in the use of nanotechnology in drug delivery. "Drug formulation companies are looking to make use of the drugs already in use, and finding better ways of delivering them using nanotechnology," professor Srinivasa Reddy told TOI.

The article goes on to state that MCOPS "has bagged major research projects" from the government in nanotech drug delivery research projects, most of them dealing with nanotech drug-delivery systems to treat life-threatening diseases such as cancer, Alzheimer's disease, heart disorders and diabetes.

Reddy said many pharmaceutical companies have used the research expertise of the MCOPS and have launched products. What MCOPS is focusing on now, he said, is nanotech drug-delivery products that can reduce costs and benefit developing countries like India.

"Over the long term, MCOPS have plans to focus nanotechnology applications into most therapeutic classes and encompass all types of formulations and delivery systems," Reddy said.

- read the story in The Times of India

Suggested Articles

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.